IFNB1 and myeloid sarcoma: As with other proteic drugs, some MS patients develop NAbs against IFNβ, which interfere with the receptor-mediated functions of IFNβ; the clinical relevance of NAbs has been the subject of debate because they appear to decrease treatment efficacy of IFNβ in those patients developing persistent, high titer NAbs [37].